Market Overview

UPDATE: Stifel Initiates Coverage on Argos Therapeutics on Positive Outlook

Related ARGS
Argos Therapeutics Licenses Arcelis(R) Technology Platform to Lummy HK for Development of Personalized Immunotherapies to Treat Cancer in China
Morning Market Losers
Argos Therapeutics: A Cure For Cancer? (Seeking Alpha)

In a report published Tuesday, Stifel analyst Joel Sendek initiated coverage on Argos Therapeutics (NASDAQ: ARGS) with a Buy rating and $16.00 price target.

In the report, Stifel noted, “We are initiating coverage of Argos Therapeutics, Inc with a Buy rating and a $16 price target. We base our price target on our expectation for positive overall survival data in 1H16 leading to 2017 approval and ultimately $653M in 2021 worldwide sales in renal cell carcinoma (RCC).

"We see the Phase II results of AGS-003 as encouraging as it implies both a survival advantage for AGS-003 as well as biomarker data that validates the underlying approach of their immune-cell based therapies. While the Phase II results from RCC were uncontrolled, the 30.2 month overall survival is more than double the 14.7 month historical overall survival in a similar patient population.”

Argos Therapeutics closed on Monday at $11.00.

Latest Ratings for ARGS

Mar 2015Roth CapitalInitiates Coverage onBuy
Feb 2015MLV & Co.Initiates Coverage onBuy
Mar 2014JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ARGS
View the Latest Analyst Ratings

Posted-In: Joel Sendek StifelAnalyst Color Initiation Analyst Ratings


Related Articles (ARGS)

Around the Web, We're Loving...